In this week’s edition of InnovationRx, we look at Aetna’s withdrawal from the ACA exchanges, the potential for digital ...

The FDA has appointed hematologist-oncologist Vinay Prasad, MD, to lead the agency’s Center for Biologics Evaluation and Research, according to a May 6 NBC News report.  As the head of CBER, Dr.

Key Takeaways Dr. Vinay Prasad has been tasked to head the FDA’s biologics divisionPrasad has criticized the U.S.

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to ...

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA ...

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...

Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...

Wall Street closed lower on Tuesday, pulled down by health care, tech and discretionary stocks. Investor mood was grim on the White House’s continued see-sawing on global trade deals, and economic ...

“Potential exposure to these substances is still quite small, thank goodness,” Jim Crotty, who served for over a decade in ...

The FTSE 100’s record run was poised to come to an end on Wednesday as pharma stocks slumped on the back of a controversial ...

Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $70 from $110 and keeps an Overweight rating on the shares. The firm notes Tuesday has been “a doozy of a day” for Sarepta, with the ...

In today's newsletter: India launches airstrikes inside Pakistan in an escalation of tensions between the two counties. The ...